208 related articles for article (PubMed ID: 11165115)
1. Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis.
Dutt M; Khuller GK
Int J Antimicrob Agents; 2001 Feb; 17(2):115-22. PubMed ID: 11165115
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles.
Dutt M; Khuller GK
J Antimicrob Chemother; 2001 Jun; 47(6):829-35. PubMed ID: 11389115
[TBL] [Abstract][Full Text] [Related]
3. Liposomes and PLG microparticles as sustained release antitubercular drug carriers--an in vitro-in vivo study.
Dutt M; Khuller GK
Int J Antimicrob Agents; 2001 Sep; 18(3):245-52. PubMed ID: 11673037
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice.
Dutt M; Khuller GK
Antimicrob Agents Chemother; 2001 Jan; 45(1):363-6. PubMed ID: 11121000
[TBL] [Abstract][Full Text] [Related]
5. Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s).
Ain Q; Sharma S; Garg SK; Khuller GK
Int J Pharm; 2002 Jun; 239(1-2):37-46. PubMed ID: 12052689
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis.
Pandey R; Zahoor A; Sharma S; Khuller GK
Tuberculosis (Edinb); 2003; 83(6):373-8. PubMed ID: 14623168
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis.
Ul-Ain Q; Sharma S; Khuller GK
Antimicrob Agents Chemother; 2003 Sep; 47(9):3005-7. PubMed ID: 12937014
[TBL] [Abstract][Full Text] [Related]
8. Poly (DL-lactide-co-glycolide) microparticles as carriers for antimycobacterial drug rifampicin.
Dutt M; Khuller GK
Indian J Exp Biol; 2000 Sep; 38(9):887-94. PubMed ID: 12561946
[TBL] [Abstract][Full Text] [Related]
9. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis.
Sharma A; Pandey R; Sharma S; Khuller GK
Int J Antimicrob Agents; 2004 Dec; 24(6):599-604. PubMed ID: 15555884
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of isoniazid release from poly(d,l-lactide-co-glycolide) matrices prepared by dry-mixing and low density polymeric foam methods.
Hsu YY; Gresser JD; Stewart RR; Trantolo DJ; Lyons CM; Simons GA; Gangadharam PR; Wise DL
J Pharm Sci; 1996 Jul; 85(7):706-13. PubMed ID: 8818994
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
Pandey R; Khuller GK
J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
[TBL] [Abstract][Full Text] [Related]
13. Antimycobacterial susceptibility evaluation of rifampicin and isoniazid benz-hydrazone in biodegradable polymeric nanoparticles against
Hakkimane SS; Shenoy VP; Gaonkar SL; Bairy I; Guru BR
Int J Nanomedicine; 2018; 13():4303-4318. PubMed ID: 30087562
[TBL] [Abstract][Full Text] [Related]
14. Effect of polymer foam morphology and density on kinetics of in vitro controlled release of isoniazid from compressed foam matrices.
Hsu YY; Gresser JD; Trantolo DJ; Lyons CM; Gangadharam PR; Wise DL
J Biomed Mater Res; 1997 Apr; 35(1):107-16. PubMed ID: 9104703
[TBL] [Abstract][Full Text] [Related]
15. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
Sharma A; Sharma S; Khuller GK
J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364
[TBL] [Abstract][Full Text] [Related]
16. The stability of insulin in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol.
Yeh MK
J Microencapsul; 2000; 17(6):743-56. PubMed ID: 11063421
[TBL] [Abstract][Full Text] [Related]
17. Protective efficacy of mycobacterial 71-kDa cell wall associated protein using poly (DL-lactide-co-glycolide) microparticles as carrier vehicles.
Dhiman N; Khuller GK
FEMS Immunol Med Microbiol; 1998 May; 21(1):19-28. PubMed ID: 9657317
[TBL] [Abstract][Full Text] [Related]
18. Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages.
Zhou H; Zhang Y; Biggs DL; Manning MC; Randolph TW; Christians U; Hybertson BM; Ng KY
J Control Release; 2005 Oct; 107(2):288-99. PubMed ID: 16009444
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs.
Pandey R; Sharma S; Khuller GK
Drug Deliv; 2006; 13(4):287-94. PubMed ID: 16766470
[TBL] [Abstract][Full Text] [Related]
20. A mesoporous silicon/poly-(DL-lactic-co-glycolic) acid microsphere for long time anti-tuberculosis drug delivery.
Xu W; Wei X; Wei K; Cao X; Zhong S
Int J Pharm; 2014 Dec; 476(1-2):116-23. PubMed ID: 25271077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
